R. B. Livingston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
R. B. Livingston has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Georgiana K. Ellis
Seattle Cancer Care Alliance, 825 Eastlake Ave East, Seattle, WA 98109-1023, USA
3 shared publications J. R. Gralow
3 shared publicationsD. Lew
2 shared publications- David A. Mankoff
Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
2 shared publications G. N. Hortobagyi
2 shared publicationsH. M. Linden
Seattle Cancer Care Alliance, Seattle, WA; Swedish Hosp Medcl Ctr, Seattle, WA; Olympic Hematology and Oncology Assoc, Bremerton, WA
2 shared publications
Latest Publications
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 1004
First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.
1004 Background: AC+G (doxorubicin 24 mg/m2/week x 15, cyclophosphamide 60 mg/m2/day po, and filgrastim daily except on the days of doxorubicin administration) produced encouraging results in a SWOG Phase II trial of pre-operative chemotherapy in locally advanced breast cancer. S0221 is a SWOG-coordinated Phase III adjuvant chemotherapy intergroup trial in node-positive and high-risk node-negative operable breast cancer, which hypothesized that the AC+G regimen is superior to ddAC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 IV and pegfilgrastim q 2 weeks x 6) and that weekly paclitaxel is superior to q 2 week paclitaxel. Methods: Between December 2003 and November 2010, 2716 patients were randomized in a 2x2 factorial design to 1) AC+G vs ddAC and 2) paclitaxel 80 mg/m2/week x 12 vs paclitaxel 175 mg/m2 q 2 weeks x 6. If there was no significant interaction between the factors, the trial was powered to find a disease-free survival hazard ratio (HR) ≤ 0.82 for weekly vs q 2 week for each factor. Results: By September 8, 2010, 349 events (161 ddAC, 188 AC+G) had occurred among 2,477 patients with follow-up, prompting the first planned interim analysis at 30% of the expected events. The arms were balanced for standard prognostic factors, and a Cox model adjusting for the paclitaxel arms had a HR = 1.21 (95% CI 0.98−1.50; p=0.071) favoring ddAC. The prescribed boundary for futility was the 99.5% CI (0.90−1.64) excluding the original alternative hypothesis that HR=0.82. No boundary was crossed for the paclitaxel comparison and there was no significant interaction of the two factors. Therefore, the Data Safety and Monitoring Committee recommended stopping randomization to the AC+G arms due to futility. Analyses by nodal-, hormone-receptor-, and HER2 status found no subset in which AC+G appeared superior. S0221 has re-opened and randomizes patients to the two paclitaxel arms after only 4 cycles of ddAC. Conclusions: Accrual will continue to 3,250 patients and ancillary studies remain ongoing. We conclude that AC+G is not superior to ddAC x 6, and do not recommend AC+G for routine use. Support: NCI grants CA32102, CA38926, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI15469, and Amgen, Inc.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 1004
First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.
1004 Background: AC+G (doxorubicin 24 mg/m2/week x 15, cyclophosphamide 60 mg/m2/day po, and filgrastim daily except on the days of doxorubicin administration) produced encouraging results in a SWOG Phase II trial of pre-operative chemotherapy in locally advanced breast cancer. S0221 is a SWOG-coordinated Phase III adjuvant chemotherapy intergroup trial in node-positive and high-risk node-negative operable breast cancer, which hypothesized that the AC+G regimen is superior to ddAC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 IV and pegfilgrastim q 2 weeks x 6) and that weekly paclitaxel is superior to q 2 week paclitaxel. Methods: Between December 2003 and November 2010, 2716 patients were randomized in a 2x2 factorial design to 1) AC+G vs ddAC and 2) paclitaxel 80 mg/m2/week x 12 vs paclitaxel 175 mg/m2 q 2 weeks x 6. If there was no significant interaction between the factors, the trial was powered to find a disease-free survival hazard ratio (HR) ≤ 0.82 for weekly vs q 2 week for each factor. Results: By September 8, 2010, 349 events (161 ddAC, 188 AC+G) had occurred among 2,477 patients with follow-up, prompting the first planned interim analysis at 30% of the expected events. The arms were balanced for standard prognostic factors, and a Cox model adjusting for the paclitaxel arms had a HR = 1.21 (95% CI 0.98−1.50; p=0.071) favoring ddAC. The prescribed boundary for futility was the 99.5% CI (0.90−1.64) excluding the original alternative hypothesis that HR=0.82. No boundary was crossed for the paclitaxel comparison and there was no significant interaction of the two factors. Therefore, the Data Safety and Monitoring Committee recommended stopping randomization to the AC+G arms due to futility. Analyses by nodal-, hormone-receptor-, and HER2 status found no subset in which AC+G appeared superior. S0221 has re-opened and randomizes patients to the two paclitaxel arms after only 4 cycles of ddAC. Conclusions: Accrual will continue to 3,250 patients and ancillary studies remain ongoing. We conclude that AC+G is not superior to ddAC x 6, and do not recommend AC+G for routine use. Support: NCI grants CA32102, CA38926, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI15469, and Amgen, Inc.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 1033
Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
1033 Background: The taxane, docetaxel (DOC), and the vinca alkaloid, vinorelbine (VNR), have significant activity in combination as first line chemotherapy for HER2-negative, stage IV breast cancer (BC). Preclinical studies suggest potential synergy between these two classes of anti-tubulin drugs. Each agent has significant activity when combined with trastuzumab in HER2-positive BC. This study evaluates both agents together with trastuzumab as first-line chemotherapy for stage IV disease. Methods: Patients (pts) with HER2-positive, metastatic BC were eligible. Pts may have received prior adjuvant chemotherapy that did not include DOC or VNR. DOC (60 mg/m2) on day 1 and VNR (27.5 mg/m2) on days 8 and 15 were given intravenously each 21-day cycle. Trastuzumab was administered concurrently (standard weekly schedule), with filgrastim days 2–21. The primary endpoint was overall survival (OS) at 1-year, with secondary outcomes of progression-free survival (PFS), response rate, and toxicity. The planned sample size was 90 pts, sufficient to estimate 1-year OS within 11% at α=0.05 (2-sided). Results: Due to slow accrual, the study was closed with a total of 76 pts registered between 2/03 and 12/06. The OS analysis includes 71 eligible pts with available data. One-year OS is 94% (95% CI 88%-100%) with a median OS of 39 months (95% CI 29–41). One-year PFS is 70% (95% CI 59%-80%) with median PFS of 19 months (95% CI 14–28). Of 63 pts with measurable disease, there were 45 (71%) CR+PRs (95% CI 59–82%). Six pts remain on treatment, with the most common reasons for discontinuation being progression (n=17) and adverse events (n=16). Of 67 pts evaluable for toxicity, 14 (21%) had a grade 4 event and 20 (30%) had a grade 3 event as the highest adverse event. Neutropenia was the predominant G 4 event. The most common G 3/4 non-hematologic toxicities were fatigue (10%) and hyperglycemia (7%). No G 5 toxicity was reported. Conclusions: The combination of docetaxel, vinorelbine, and trastuzumab is very active as first-line chemotherapy in HER2-positive, stage IV breast cancer and has the best survival rate published to date in this population.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 1033
Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
1033 Background: The taxane, docetaxel (DOC), and the vinca alkaloid, vinorelbine (VNR), have significant activity in combination as first line chemotherapy for HER2-negative, stage IV breast cancer (BC). Preclinical studies suggest potential synergy between these two classes of anti-tubulin drugs. Each agent has significant activity when combined with trastuzumab in HER2-positive BC. This study evaluates both agents together with trastuzumab as first-line chemotherapy for stage IV disease. Methods: Patients (pts) with HER2-positive, metastatic BC were eligible. Pts may have received prior adjuvant chemotherapy that did not include DOC or VNR. DOC (60 mg/m2) on day 1 and VNR (27.5 mg/m2) on days 8 and 15 were given intravenously each 21-day cycle. Trastuzumab was administered concurrently (standard weekly schedule), with filgrastim days 2–21. The primary endpoint was overall survival (OS) at 1-year, with secondary outcomes of progression-free survival (PFS), response rate, and toxicity. The planned sample size was 90 pts, sufficient to estimate 1-year OS within 11% at α=0.05 (2-sided). Results: Due to slow accrual, the study was closed with a total of 76 pts registered between 2/03 and 12/06. The OS analysis includes 71 eligible pts with available data. One-year OS is 94% (95% CI 88%-100%) with a median OS of 39 months (95% CI 29–41). One-year PFS is 70% (95% CI 59%-80%) with median PFS of 19 months (95% CI 14–28). Of 63 pts with measurable disease, there were 45 (71%) CR+PRs (95% CI 59–82%). Six pts remain on treatment, with the most common reasons for discontinuation being progression (n=17) and adverse events (n=16). Of 67 pts evaluable for toxicity, 14 (21%) had a grade 4 event and 20 (30%) had a grade 3 event as the highest adverse event. Neutropenia was the predominant G 4 event. The most common G 3/4 non-hematologic toxicities were fatigue (10%) and hyperglycemia (7%). No G 5 toxicity was reported. Conclusions: The combination of docetaxel, vinorelbine, and trastuzumab is very active as first-line chemotherapy in HER2-positive, stage IV breast cancer and has the best survival rate published to date in this population.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 633
Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
633 Background: The response of bone-dominant breast cancer to therapy is difficult to assess by conventional imaging approaches such as bone scan and MRI. Our preliminary studies have previously shown that quantitative serial [F-18]-2-fluoro-D-glucose positron emission tomography (FDG PET) correlates with therapeutic response of bone-dominant breast cancer, but the relationship to long-term outcome measures is unknown. The aim of this study is to evaluate the prognostic power of FDG PET imaging in bone-dominant breast cancer undergoing treatment. Methods: A retrospective analysis was performed on the medical records of 405 breast cancer patients who were previously referred for FDG PET between January 1999 and December 2003. From this population of patients, 29 patients were selected who demonstrated metastatic bone only +/- nodal breast cancer and were undergoing treatment with at least 2 serial PET scans which had clear uptake. The standard uptake value (SUV) changes for the most conspicuous bone lesion were compared to long-term prognostic outcomes (TTP, time to skeletal-related event(t-SRE), and time to death(TTD)). Time-to-progression was defined as the time from the initial index FDG PET to disease progression (>25% increase in tumor markers, clear symptomatic progression, progression on some other imaging modality, skeletal-related events, or a new lesion). A skeletal-related event was defined by hypercalcemia, radiation therapy to stabilize disease, pathologic fracture, cord compression, or surgery to stabilize spine. Results: Using hazard analysis, longer TTP correlated with greater decreases in SUV either by absolute or percentage changes. T-SRE was found to significantly correlate with higher initial SUV readings. In addition, when grouped by tertiles for absolute SUV changes, the smallest and largest tertile groups correlated with t-SRE. No correlation was demonstrated for TTD and SUV changes, however only one death occurred during this study analysis. Conclusions: Preliminary results indicate that serial FDG PET predicts TTP and t-SRE in bone-dominant breast cancer; however, larger prospective trials are needed. Supported by CA72064, CA42045, and BCRF No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 633
Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
633 Background: The response of bone-dominant breast cancer to therapy is difficult to assess by conventional imaging approaches such as bone scan and MRI. Our preliminary studies have previously shown that quantitative serial [F-18]-2-fluoro-D-glucose positron emission tomography (FDG PET) correlates with therapeutic response of bone-dominant breast cancer, but the relationship to long-term outcome measures is unknown. The aim of this study is to evaluate the prognostic power of FDG PET imaging in bone-dominant breast cancer undergoing treatment. Methods: A retrospective analysis was performed on the medical records of 405 breast cancer patients who were previously referred for FDG PET between January 1999 and December 2003. From this population of patients, 29 patients were selected who demonstrated metastatic bone only +/- nodal breast cancer and were undergoing treatment with at least 2 serial PET scans which had clear uptake. The standard uptake value (SUV) changes for the most conspicuous bone lesion were compared to long-term prognostic outcomes (TTP, time to skeletal-related event(t-SRE), and time to death(TTD)). Time-to-progression was defined as the time from the initial index FDG PET to disease progression (>25% increase in tumor markers, clear symptomatic progression, progression on some other imaging modality, skeletal-related events, or a new lesion). A skeletal-related event was defined by hypercalcemia, radiation therapy to stabilize disease, pathologic fracture, cord compression, or surgery to stabilize spine. Results: Using hazard analysis, longer TTP correlated with greater decreases in SUV either by absolute or percentage changes. T-SRE was found to significantly correlate with higher initial SUV readings. In addition, when grouped by tertiles for absolute SUV changes, the smallest and largest tertile groups correlated with t-SRE. No correlation was demonstrated for TTD and SUV changes, however only one death occurred during this study analysis. Conclusions: Preliminary results indicate that serial FDG PET predicts TTP and t-SRE in bone-dominant breast cancer; however, larger prospective trials are needed. Supported by CA72064, CA42045, and BCRF No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 628
Adjuvant weekly “AC+G” followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
628 We have previously reported DFS for the adjuvant treatment of node-positive breast cancer with a median of 4 involved nodes of 86% at 5 years using a 20–24 week regimen of weekly doxorubicin (20–24 mg/m2), daily oral cyclophosphamide (60 mg/m2) ± weekly 5FU (300 mg/m2) and scheduled filgrastim support (5 mcg/kg/day, days 2–7) (“ AC+G,” Ellis G et al JCO 2002 20(17): 3637–3643). We report now on 54 patients treated on a Seattle Cancer Care Alliance/University of Washington successor study with 12 weeks of AC+G followed by 12 weeks of weekly paclitaxel (80 mg/m2). Median age was 50. Median number of involved nodes was 5, with 33% having 1–3, 39% with 4–9, and 28% > 10 involved nodes 41/54 patients had either 4 or more involved nodes, OR ER/PR negative disease OR HER-2/neu positive disease (3+ by IHC, or FISH+). Eighty percent had ER positive disease, 22% had HER-2/neu positive disease. Grade 3–4 toxicities, for the “ AC+G” or paclitaxel portion of treatment, were as follows, respectively: neutropenia 11%, 23% febrile neutropenia 0%, 2% mucositis 6%, 0% hand-foot syndrome 7%, 0% RBC transfusion 4%, 2% nausea, vomiting 2%, 0%. Additional hormonal therapy was administered for patients with ER or PR positive disease: tamoxifen in 31%, tamoxifen followed by an aromatase inhibitor, 13% aromatase inhibitor 31% aromatase inhibitor followed by tamoxifen 2%. Disease-free survival at 3 years is 90% compared to 86% in the previous study, (F)AC+G. By way of further comparison, Citron et al reported a DFS of 82% at 4 years for CALGB 9741 for patients with a median of 3 positive nodes.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 628
Adjuvant weekly “AC+G” followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
628 We have previously reported DFS for the adjuvant treatment of node-positive breast cancer with a median of 4 involved nodes of 86% at 5 years using a 20–24 week regimen of weekly doxorubicin (20–24 mg/m2), daily oral cyclophosphamide (60 mg/m2) ± weekly 5FU (300 mg/m2) and scheduled filgrastim support (5 mcg/kg/day, days 2–7) (“ AC+G,” Ellis G et al JCO 2002 20(17): 3637–3643). We report now on 54 patients treated on a Seattle Cancer Care Alliance/University of Washington successor study with 12 weeks of AC+G followed by 12 weeks of weekly paclitaxel (80 mg/m2). Median age was 50. Median number of involved nodes was 5, with 33% having 1–3, 39% with 4–9, and 28% > 10 involved nodes 41/54 patients had either 4 or more involved nodes, OR ER/PR negative disease OR HER-2/neu positive disease (3+ by IHC, or FISH+). Eighty percent had ER positive disease, 22% had HER-2/neu positive disease. Grade 3–4 toxicities, for the “ AC+G” or paclitaxel portion of treatment, were as follows, respectively: neutropenia 11%, 23% febrile neutropenia 0%, 2% mucositis 6%, 0% hand-foot syndrome 7%, 0% RBC transfusion 4%, 2% nausea, vomiting 2%, 0%. Additional hormonal therapy was administered for patients with ER or PR positive disease: tamoxifen in 31%, tamoxifen followed by an aromatase inhibitor, 13% aromatase inhibitor 31% aromatase inhibitor followed by tamoxifen 2%. Disease-free survival at 3 years is 90% compared to 86% in the previous study, (F)AC+G. By way of further comparison, Citron et al reported a DFS of 82% at 4 years for CALGB 9741 for patients with a median of 3 positive nodes.
- 1 June 1999
- Vol. 85 (11) , 2410-23
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown to be inaccurate. The authors studied the feasibility and accuracy of [technetium 99m]-sestamibi (MIBI) for monitoring the response of patients with LABC to neoadjuvant chemotherapy. Patients receiving neoadjuvant chemotherapy for LABC underwent prone lateral scintimammography before therapy, after 2 months of therapy, and close to the completion of chemotherapy (presurgery) if chemotherapy continued for >3 months. Images were analyzed both qualitatively and quantitatively using the lesion-to-normal breast MIBI uptake ratio (L:N). Imaging results were compared with the clinical response and the pathologic response as determined from the posttherapy surgical specimen. A total of 32 patients (29 who were assessable for primary tumor response and 28 who were assessable for lymph node response) were included in the study. The mean change in the primary tumor L:N MIBI uptake ratio after 2 months of chemotherapy was -35% for clinical responders and +17% for nonresponders (P or =40% in the MIBI uptake ratio identified CRs with 100% sensitivity and 89% specificity. Pretherapy imaging predicted axillary lymph node metastases in 85% of patients ultimately found to have > or =1 positive lymph nodes at surgery, but was less accurate in identifying residual lymph node disease after therapy (55% sensitivity and 75% specificity). MIBI imaging accurately assessed the response to neoadjuvant chemotherapy in patients with LABC. Further studies are needed to determine the role of MIBI in this group of patients.
- 1 June 1999
- Vol. 85 (11) , 2410-23
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown to be inaccurate. The authors studied the feasibility and accuracy of [technetium 99m]-sestamibi (MIBI) for monitoring the response of patients with LABC to neoadjuvant chemotherapy. Patients receiving neoadjuvant chemotherapy for LABC underwent prone lateral scintimammography before therapy, after 2 months of therapy, and close to the completion of chemotherapy (presurgery) if chemotherapy continued for >3 months. Images were analyzed both qualitatively and quantitatively using the lesion-to-normal breast MIBI uptake ratio (L:N). Imaging results were compared with the clinical response and the pathologic response as determined from the posttherapy surgical specimen. A total of 32 patients (29 who were assessable for primary tumor response and 28 who were assessable for lymph node response) were included in the study. The mean change in the primary tumor L:N MIBI uptake ratio after 2 months of chemotherapy was -35% for clinical responders and +17% for nonresponders (P or =40% in the MIBI uptake ratio identified CRs with 100% sensitivity and 89% specificity. Pretherapy imaging predicted axillary lymph node metastases in 85% of patients ultimately found to have > or =1 positive lymph nodes at surgery, but was less accurate in identifying residual lymph node disease after therapy (55% sensitivity and 75% specificity). MIBI imaging accurately assessed the response to neoadjuvant chemotherapy in patients with LABC. Further studies are needed to determine the role of MIBI in this group of patients.
- 1 April 1997
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (4) , 1395-1400
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
PURPOSE: We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgrastim) in an attempt to maximize delivered dose-intensity (DDI). Objective tumor response, DDI, and toxicity were assessed, as well as time to progression (TTP) and survival. PATIENTS AND METHODS: This single-center nonrandomized trial enrolled 40 patients. Anthracycline exposure and subsequent progression were common to all patients, and 38 of 40 were paclitaxel-refractory. Vinorelbine was given initially at 30 mg/m2/wk, then at 35 mg/m2/wk in a phase I/II design, which involved first intermittent (6 days of 7) and then continuous (daily) administration of G-CSF at 5 micrograms/kg. RESULTS: The maximum-tolerated starting dose was 35 mg/m2/wk with continuous G-CSF support. The mean DDI was 27.7 mg/m2/wk for all patients. There were two complete responses (CRs) and eight partial responses (PRs) in 40 assessable patients for an overall response rate of 25% (95% confidence interval [CI], 13% to 41%). The median TTP was 13 weeks and median survival time 33 weeks. The dose-limiting toxicity was neutropenia, with dose delay or reduction required in 14 of 27 patients entered at 35 mg/m2. Febrile neutropenia that required hospitalization was unusual (three of 40 patients, 8%). There were no treatment-related deaths. Grade 3/4 thrombocytopenia occurred in nine patients (23%) and 26 patients (65%) required RBC transfusions for anemia. Seven patients (18%) had reversible grade 3/4 nonhematologic complications, primarily related to neurotoxicity. Grade > or = 3 mucositis was absent. CONCLUSION: Concurrent administration of weekly vinoralbine and daily G-CSF is feasible and permits an increase in DDI for vinorelbine of 43% to 76% over that reported in series without growth factor support. The response rate, TTP, and survival data are encouraging for therapy given to heavily pretreated patients with metastatic breast cancer. Vinorelbine is not cross-resistant with paclitaxel and should be considered for further trials in the dose-intensified mode made possible by G-CSF, alone or combined with other agents.
- 1 April 1997
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (4) , 1395-1400
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
PURPOSE: We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgrastim) in an attempt to maximize delivered dose-intensity (DDI). Objective tumor response, DDI, and toxicity were assessed, as well as time to progression (TTP) and survival. PATIENTS AND METHODS: This single-center nonrandomized trial enrolled 40 patients. Anthracycline exposure and subsequent progression were common to all patients, and 38 of 40 were paclitaxel-refractory. Vinorelbine was given initially at 30 mg/m2/wk, then at 35 mg/m2/wk in a phase I/II design, which involved first intermittent (6 days of 7) and then continuous (daily) administration of G-CSF at 5 micrograms/kg. RESULTS: The maximum-tolerated starting dose was 35 mg/m2/wk with continuous G-CSF support. The mean DDI was 27.7 mg/m2/wk for all patients. There were two complete responses (CRs) and eight partial responses (PRs) in 40 assessable patients for an overall response rate of 25% (95% confidence interval [CI], 13% to 41%). The median TTP was 13 weeks and median survival time 33 weeks. The dose-limiting toxicity was neutropenia, with dose delay or reduction required in 14 of 27 patients entered at 35 mg/m2. Febrile neutropenia that required hospitalization was unusual (three of 40 patients, 8%). There were no treatment-related deaths. Grade 3/4 thrombocytopenia occurred in nine patients (23%) and 26 patients (65%) required RBC transfusions for anemia. Seven patients (18%) had reversible grade 3/4 nonhematologic complications, primarily related to neurotoxicity. Grade > or = 3 mucositis was absent. CONCLUSION: Concurrent administration of weekly vinoralbine and daily G-CSF is feasible and permits an increase in DDI for vinorelbine of 43% to 76% over that reported in series without growth factor support. The response rate, TTP, and survival data are encouraging for therapy given to heavily pretreated patients with metastatic breast cancer. Vinorelbine is not cross-resistant with paclitaxel and should be considered for further trials in the dose-intensified mode made possible by G-CSF, alone or combined with other agents.